Cell and gene therapy market developments highlight growing demands for clinical evidence and patient access, as individualized gene editing, safety investigations, new cellular therapy indications and evolving regulatory pathways influence competitive differentiation and commercialization strategies.
Coverage Period: October 6 – November 11, 2026
Introduction
The defining story of this reporting period is the divergence between expanding clinical opportunities for cell and gene therapies and mounting evidence that safety, durability, and patient access will determine which approaches advance.
Encouraging results across oncology, rare genetic diseases, and autoimmune disorders demonstrate the therapeutic reach of advanced modalities. Yet the discontinuation of an autoimmune cell therapy program and renewed regulatory scrutiny of AAV-associated tumor risks expose significant development challenges.
At the same time, new FDA guidance and proposed changes to Medicaid reimbursement arrangements could address long-standing barriers to individualized treatment and commercialization.
These developments are reshaping how developers, investors, and regulators assess the clinical and commercial potential of advanced therapies.
Companies covered: Novartis, Artiva Biotherapeutics, Iovance Biotherapeutics, CRISPR Therapeutics, uniQure, Lyell Immunopharma Clinical areas covered: Spinal muscular atrophy (SMA), Autoimmune diseases, Soft tissue sarcoma, Huntington’s disease, Inherited retinal diseases, Oncology, Rare Diseases
Executive Summary
- Regulatory flexibility and reimbursement innovation could improve access to advanced therapies. The FDA’s proposed framework for individualized genome-editing products and CMS plans to expand outcomes-based reimbursement arrangements could reduce development and access barriers, particularly in rare genetic diseases. Implementation details and manufacturer participation remain important uncertainties.
- Long-term safety and treatment durability are becoming critical competitive differentiators. The FDA’s investigation of tumor risks associated with AAV-based gene therapy and Artiva’s discontinuation of its autoimmune natural killer cell program highlight distinct risks facing advanced therapies. These developments reinforce the importance of sustained efficacy, treatment-regimen safety, and long-term monitoring.
- Next-generation cellular therapies are extending into new oncology and autoimmune indications. Early signals from tumor-infiltrating lymphocyte therapy, dual-targeting CAR-T platforms, and allogeneic CAR-T approaches support continued exploration beyond established treatment settings. Larger studies and longer follow-up will determine how these platforms compare with existing alternatives.
- Evidence-generation strategies are diverging across cell and gene therapy markets. uniQure’s accelerated approval application in Huntington’s disease and Lyell’s head-to-head CAR-T development program illustrate how clinical evidence strategies differ between rare diseases with limited treatment options and indications with established advanced therapies. Evidence suited to both regulatory review and clinical decision-making may become a more important source of competitive differentiation.
Watch the video summary
Strategic Perspective on Four Key Developments in Cell and Gene Therapy
Individualized Gene Editing and CMS Medicaid Access Models Could Support Rare Disease Commercialization
Regulatory flexibility and reimbursement innovation emerged as closely connected developments during the reporting period, particularly for rare genetic diseases.
On October 27, the FDA introduced draft guidance for individualized genome-editing therapies, proposing an Individualized Feature Space framework that could accommodate multiple patient-specific treatment variants within a single biologics license application.
For developers targeting ultra-rare genetic mutations, this approach may reduce the need to repeat clinical development programs for every treatment variation. It could also make platform-based development strategies more practical, provided product variants meet predefined safety, manufacturing, and activity requirements.
CMS simultaneously outlined plans to expand its Cell and Gene Therapy Access Model beyond sickle cell disease. The model uses centralized negotiations and outcomes-based agreements to help Medicaid programs manage the cost and uncertainty associated with advanced therapies.
The commercial relevance extends beyond reimbursement. Developers may need to incorporate long-term outcomes measurement, manufacturing comparability, and payer evidence requirements into development planning.
Together, these policy initiatives could create a more workable pathway from individualized treatment development to patient access.
Key Uncertainty: The FDA framework remains draft guidance, and the scope of CMS expansion has not been finalized. Their impact will depend on regulatory implementation, manufacturer participation, and the practicality of measuring long-term outcomes across small patient populations.
AAV Gene Therapy Safety and Autoimmune Cell Therapy Durability Face Greater Scrutiny: Zolgensma and Artiva’s AlloNK
Safety and durability concerns became particularly consequential during the period, exposing different vulnerabilities within advanced therapy development.
The FDA’s investigation into tumors reported following treatment with Zolgensma renewed attention to insertional oncogenesis, a potential risk associated with AAV vector integration into the human genome.
Molecular evidence of vector integration in tumor tissue has raised questions about the adequacy of existing long-term monitoring requirements. However, the FDA maintained that the benefits of Zolgensma and Itvisma continue to outweigh their potential risks.
In autoimmune disease, Artiva’s discontinuation of its AlloNK program exposed a separate challenge. Longer-term follow-up failed to demonstrate the durability needed to support continued development, while two patient deaths raised concerns about the overall treatment regimen. One death was considered likely related to lymphodepleting chemotherapy; the other was assessed as unrelated to treatment, with its cause unknown.
The setback follows previously reported pauses in autoimmune CAR-T development at other companies, reinforcing the need to assess conditioning regimens alongside cellular therapies.
For developers, these events highlight the importance of safety surveillance, durable disease control, and carefully defined risk-benefit profiles.
They may also influence investment decisions and competitive positioning, particularly where treatment aims to deliver lasting benefits after a single administration.
Key Uncertainty: It remains unclear whether current investigations and clinical setbacks will primarily affect individual products or lead to more extensive monitoring and evidence requirements across particular cell and gene therapy platforms.
CAR-T, TIL and Ophthalmic Gene Therapies Explore New Indications: Iovance, Lyell, CRISPR and Atsena
Expansion beyond established indications remains an important growth strategy, with developers pursuing opportunities across solid tumors, autoimmune diseases, and inherited retinal disorders.
In oncology, Iovance reported a 50% confirmed objective response rate among eight evaluable patients receiving lifileucel in refractory soft tissue sarcomas. Although the dataset remains small, the findings support further investigation of tumor-infiltrating lymphocyte therapy in cancers with limited treatment options.
Next-generation CAR-T platforms are also moving toward broader applications. Lyell is advancing its dual-targeting CD19/CD20 therapy, ronde-cel, in large B-cell lymphoma while developing a GCC-targeted CAR-T candidate for metastatic colorectal cancer.
In autoimmune disease, CRISPR Therapeutics reported encouraging early responses with its gene-edited allogeneic CD19-directed CAR-T therapy, zugo-cel, across systemic sclerosis, inflammatory myopathies, and lupus. These findings are particularly relevant as other autoimmune cell therapy programs face durability and safety challenges.
Meanwhile, Atsena’s ophthalmic gene therapy demonstrated improvements in retinal sensitivity among patients with X-linked retinoschisis, supporting continued pivotal development.
These programs reflect several distinct expansion strategies: applying established modalities to new diseases, engineering cells to improve therapeutic performance, and targeting conditions with few disease-specific treatments.
For companies, successful expansion could improve platform economics and extend commercial opportunities beyond initial indications.
Key Uncertainty: Small cohorts, heterogeneous endpoints, and limited long-term follow-up make it difficult to determine which approaches will deliver reproducible clinical benefits or commercially viable treatment models.
Accelerated Approval and Comparative CAR-T Trials Highlight Diverging Evidence Strategies: uniQure and Lyell
As cell and gene therapies approach regulatory decisions, the design of clinical evidence is becoming an important determinant of competitive positioning.
The reporting period highlights two distinct development strategies. In Huntington’s disease, uniQure’s gene therapy application received FDA priority review under the accelerated approval pathway, supported by Phase I/II data compared with an external natural-history control. A planned randomized confirmatory study will assess clinical benefit using Total Functional Capacity as its primary endpoint.
In large B-cell lymphoma, Lyell is pursuing a different approach with its dual-targeting CD19/CD20 CAR-T therapy, ronde-cel. Its development program combines a single-arm pivotal trial in later-line disease with a randomized head-to-head study against approved CAR-T therapies in the second-line setting.
The distinction reflects different competitive environments. In rare diseases with limited treatment alternatives, regulatory pathways may accommodate unconventional evidence-generation strategies. In markets where advanced therapies are already established, comparative clinical evidence could become more important for demonstrating differentiation.
For developers, this creates a strategic choice between pursuing earlier regulatory access and investing in evidence that may support longer-term clinical adoption and competitive positioning. These approaches are not necessarily mutually exclusive, but they carry different development costs, timelines, and evidence requirements.
Key Uncertainty: It remains unclear how regulators will assess the strength of externally controlled evidence in Huntington’s disease or whether head-to-head CAR-T trials will establish meaningful differentiation in clinical outcomes. The extent to which these strategies influence payer decisions and treatment adoption also remains uncertain.
What We Are Watching Next in Cell and Gene Therapy Safety, Regulation and Clinical Development
- AAV gene therapy safety: Findings from the Zolgensma investigation and potential implications for long-term monitoring, labeling, and AAV vector development.
- Rare disease regulation and reimbursement: Finalization of individualized genome-editing guidance and the structure of expanded CMS outcomes-based agreements.
- Autoimmune CAR-T durability: Longer follow-up from allogeneic CAR-T studies, including zugo-cel, to assess sustained responses and treatment-regimen safety.
- Oncology cell therapy evidence: Upcoming pivotal data for ronde-cel and further validation of lifileucel in refractory soft tissue sarcomas.
- Huntington’s disease gene therapy: uniQure’s May 2027 FDA decision and progress toward its randomized confirmatory study.
Key Takeaway: Durable Efficacy, Safety and Patient Access Become Competitive Priorities
The October–November reporting period reveals a widening distinction between the clinical promise of cell and gene therapies and the evidence required to support their long-term adoption.
Regulatory innovation and expanding clinical applications create opportunities for developers, but safety investigations, durability setbacks, and demanding evidence-generation requirements demonstrate that technological advances do not automatically translate into viable treatments.
The strongest competitive positions may emerge among companies that can demonstrate sustained clinical benefit, manage treatment-related risks, and align regulatory development with reimbursement and commercialization requirements.
The market is moving toward a more demanding definition of success: durable efficacy, credible long-term safety, and practical patient access must advance together.
🌐 Explore LucidQuest Strategic Roundups across multiple therapy areas for deeper healthcare and pharma analysis
About LucidQuest
LucidQuest helps organizations anticipate change by identifying emerging signals, market shifts, and strategic opportunities.
Learn more: www.lqventures.com
Contact us at: info@lqventures.com
For cell and gene therapy strategy, competitive intelligence and wargaming, see LucidCGT